A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Study ID
NCT02900664

Study type
Interventional

Study phase
Phase 1

Study status
Active, not recruiting

Trial Acronym

Trial Summary

The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

More informations

Trial Starting Date

Aug 23,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

290

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

In order to facilitate the use of our website, we use cookies.